

file copy

L2 ANSWER 3 OF 233 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2000:867130 CAPLUS  
 DOCUMENT NUMBER: 134:278558  
 TITLE: The role of parathyroid hormone and **hyperparathyroidism** in **osteoporosis**  
 AUTHOR(S): D'Amour, Pierre  
 CORPORATE SOURCE: Department of Medicine, Universite de Montreal, Centre de Recherche Clinique, Hopital St Luc, Montreal, QC, H2X 1P1, Can.  
 SOURCE: Osteoporosis Primer (2000), 211-224. Editor(s): Henderson, Janet E.; Goltzman, David. Cambridge University Press: Cambridge, UK. CODEN: 69ASDQ  
 DOCUMENT TYPE: Conference; General Review  
 LANGUAGE: English  
 AB A review, with 68 refs., discussing how PTH and factors affecting PTH concn. and/or biol. effects are involved in the development of primary and secondary osteoporosis.  
 REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 53 OF 233 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1998:300469 CAPLUS  
 DOCUMENT NUMBER: 129:600  
 TITLE: Chromogranin A peptides for treatment of hyperparathyroidism and related diseases  
 INVENTOR(S): Angeletti, Ruth Hogue; Russell, John  
 PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA  
 SOURCE: U.S., 15 pp., Cont.-in-part of U.S. 5,514,775. CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5747454	A	19980505	US 1995-491544	19950616
US 5514775	A	19960507	US 1993-75391	19930609
PRIORITY APPLN. INFO.:			US 1993-75391	19930609

OTHER SOURCE(S): MARPAT 129:600  
 AB This invention relates to synthetic chromogranin A peptides, pharmaceutical compns. comprising these peptides, and uses of the peptides for treating **hyperparathyroidism**, and treating or preventing conditions assocd. with **hyperparathyroidism** such as parathyroid hyperplasia-assocd. renal failure, **osteoporosis**, and the like.  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 113 OF 233 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1994:576315 CAPLUS  
 DOCUMENT NUMBER: 121:176315  
 TITLE: Characteristics of bone mass change in secondary osteoporosis  
 AUTHOR(S): Fukunaga, Masao  
 CORPORATE SOURCE: Kawasaki Med. Sch., Kurashiki, 701-01, Japan  
 SOURCE: Clinical Calcium (1994), 4(8), 1099-101  
 CODEN: CLCCEJ; ISSN: 0917-5857

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review, with 9 refs., on characteristics of the change of bone mineral content in **osteoporosis**. **Osteoporosis** induced by primary or secondary **hyperparathyroidism**, hyperthyroidism, gastrectomy, steroid loading, NIDDM or ovariectomy was discussed.

L2 ANSWER 103 OF 233 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1995:708303 CAPLUS

DOCUMENT NUMBER: 123:195162

TITLE: Developmental mechanism and management of osteoporosis induced by endocrine disorder

AUTHOR(S): Kurabayashi, Takumi

CORPORATE SOURCE: Sch. Med., Niigata Univ., Niigata, 951, Japan

SOURCE: Rinsho to Yakubutsu Chiryo (1995), 14(6), 521-4

CODEN: RYCHEI; ISSN: 0913-7505

PUBLISHER: Mikusu

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review, with 5 refs., on developmental mechanism and management of **osteoporosis** induced by endocrine disorder, discussing inducing mechanism of **osteoporosis** in primary **hyperparathyroidism**, thyroid function disorders, in Cushing's disease, in acromegaly, and in hyperprolactinemia.

=>

L1 ANSWER 1 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:258365 USPATFULL  
 TITLE: Pharmaceutical composition  
 INVENTOR(S): Kumakura, Seichiro, Saitama-shi, JAPAN  
 Nakajima, Tomoko, Tokyo, JAPAN  
 PATENT ASSIGNEE(S): SANKYO COMPANY, LIMITED, Tokyo, JAPAN (non-U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181418	A1	20030925
APPLICATION INFO.:	US 2003-377230	A1	20030228 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2002-55356	20020301
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FRISHAUF, HOLTZ, GOODMAN & CHICK, PC, 767 THIRD AVENUE, 25TH FLOOR, NEW YORK, NY, 10017-2023	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1208	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition which contains (i) a complex of (a) one or more OCIF substances selected from the group consisting of an osteoclastogenesis inhibitory factor, an analog thereof and a variant thereof, and (b) a polysaccharide substance comprising a polysaccharide or a derivative thereof and (ii) a substance suppressing production of a prostaglandin and/or a substance competing an action of a prostaglandin. The invention also provides a method for treatment or prevention of a bone metabolic disease by administering to a patient in need thereof, an effective amount of (i) a complex of (a) one or more OCIF substances selected from the group consisting of an osteoclastogenesis inhibitory factor, an analog thereof and a variant thereof, and (b) a polysaccharide substance comprising a polysaccharide or a derivative thereof, and of (ii) a substance suppressing production of prostaglandin and/or a substance competing an action of prostaglandin.

SUMM . . . Bone metabolic disease in the present invention may include: primary osteoporosis (senile osteoporosis, postmenopausal osteoporosis and idiopathic juvenile osteoporosis), and **endocrine osteoporosis** (hyperthyroidism, **hyperparathyroidism**, Cushing's syndrome and acromegaly), and osteoporosis accompanying hypogonadism (hypopituitarism, a Klinefelter syndrome and a Turner syndrome), hereditary and congenital osteoporosis. . .

L1 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:207826 USPATFULL  
 TITLE: OPG FUSION PROTEIN COMPOSITIONS AND METHODS  
 INVENTOR(S): DUNSTAN, COLIN R., THOUSAND OAKS, CA, UNITED STATES  
 WOODEN, SCOTT K., THOUSAND OAKS, CA, UNITED STATES  
 MANN, MICHAEL B., THOUSAND OAKS, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144187	A1	20030731
APPLICATION INFO.:	US 1999-389782	A1	19990903 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER  
DRIVE, THOUSAND OAKS, CA, 91320-1799

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 1616

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to OPG fusion protein compositions, methods of preparation of such compositions and uses thereof. More particularly, the present invention relates to a fusion protein comprising an OPG polypeptide and an immunoglobulin FC region.

DETD [0093] Osteoporosis, such as primary osteoporosis, **endocrine osteoporosis** (hyperthyroidism, hyperparathyroidism, Cushing's syndrome, and acromegaly), hereditary and congenital forms of osteoporosis (osteogenesis imperfecta, homocystinuria, Menkes' syndrome, and Riley-Day syndrome). . . tumors (breast, lung and kidney) and hematologic malignancies (multiple myeloma, lymphoma and leukemia), idiopathic hypercalcemia, and hypercalcemia associated with hyperthyroidism, **hyperparathyroidism**, sarcoid, and renal function disorders; osteopenia following surgery, induced by steroid administration, and associated with disorders of the small and. . .

L1 ANSWER 3 OF 6 USPTFULL on STN

ACCESSION NUMBER: 2003:201340 USPTFULL

TITLE: Complex comprising OCIF and polysaccharide

INVENTOR(S): Yamamoto, Shinichi, Tokyo, JAPAN  
Okada, Junichi, Yokohama-shi, JAPAN  
Kurihara, Atsushi, Yokohama-shi, JAPAN  
Numazawa, Taku, Saitama-shi, JAPAN  
Kondo, Junichi, Yokohama-shi, JAPAN  
Tsuda, Eisuke, Tokyo, JAPAN  
Mochizuki, Shinichi, Kawachi-gun, JAPAN  
Nishi, Hirotaka, Yokohama-shi, JAPAN  
Miyazaki, Hideki, Kashiwa-shi, JAPAN

PATENT ASSIGNEE(S): SANKYO COMPANY, LIMITED, Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003139325	A1	20030724
APPLICATION INFO.:	US 2003-364045	A1	20030211 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-183091, filed on 27 Jun 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-198985	20010629
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FRISHAUF, HOLTZ, GOODMAN & CHICK, PC, 767 THIRD AVENUE, 25TH FLOOR, NEW YORK, NY, 10017-2023	
NUMBER OF CLAIMS:	92	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2352	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A complex comprising at least one substance selected from the group consisting of an osteoclastogenesis inhibitory factor, an analogue thereof and a variant thereof, which is bound to at least one substance selected from the group consisting of a polysaccharide and a polysaccharide derivative. The complex has a prolonged retention in the

bloodstream after administration, making it useful in the treatment and prophylaxis of bone metabolic diseases.

SUMM . . . or prevented by the complex of the present invention include: primary osteoporosis (senile osteoporosis, postmenopausal osteoporosis and idiopathic juvenile osteoporosis); **endocrine osteoporosis** (hyperthyroidism, **hyperparathyroidism**, Cushing's syndrome and acromegaly); osteoporosis accompanying hypogonadism (hypopituitarism, Klinefelter syndrome and Turner syndrome); hereditary and congenital osteoporosis (osteogenesis imperfecta, homocystinuria, . . .

L1 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:57090 USPATFULL

TITLE: Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein

INVENTOR(S): Kostenuik, Paul, Newbury Park, CA, UNITED STATES

Liu, Chuan-Fa, Longmont, CO, UNITED STATES

Lacey, David Lee, Newbury Park, CA, UNITED STATES

PATENT ASSIGNEE(S): Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003039654	A1	20030227
APPLICATION INFO.:	US 2001-843221	A1	20010426 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266673P	20010206 (60)
	US 2000-214860P	20000628 (60)
	US 2000-200053P	20000427 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799	
NUMBER OF CLAIMS:	79	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	2877	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise:

(a) a PTH/PTHrP modulating domain; and

(b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Such peptides typically will be modulators of both PTH activity and PTHrP activity, although such techniques can be used to generate peptide sequences that serve as selective modulators (e.g., agonists of PTH activity but not PTHrP activity).

DETD [0229] primary and secondary **hyperparathyroidism**;

DETD [0236] **endocrine osteoporosis** (hyperthyroidism, **hyperparathyroidism**, Cushing's syndrome, and acromegaly);

DETD [0254] **endocrine osteoporosis** (hyperthyroidism, Cushing's syndrome, and acromegaly);

DETD [0315] Several disease states are associated with increased circulating levels of PTH or PTHrP. Primary and secondary **hyperparathyroidism** (PHPT and SHPT, respectively), are associated with increased PTH levels, while humoral hypercalcemia of malignancy (HHM) results in elevated PTHrP. . . .

DETD . . . chronic hypercalcemia, we used PTH-(1-34)-Fc as a long-acting calcemic agent. This study also represents a model for primary and secondary **hyperparathyroidism**, diseases which are characterized by persistent elevation of PTH levels. In vehicle-treated mice, a single SC injection of PTH-(1-34)-Fc (30. . . .

DETD . . . PTHrP sequences. These data suggest that [Asn10,Leu11]PTHrP-(7-34)-Fc, as well as other Fc-conjugated PTH-R1 antagonists, may be effective treatment options for **hyperparathyroidism**, HHM, and other diseases associated with aberrant PTH-R1 signaling.

L1 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:300820 USPATFULL

TITLE: Integrin/adhesion antagonists

INVENTOR(S): Feige, Ulrich, Newbury Park, CA, UNITED STATES  
Kohno, Tadahiko, Thousand Oaks, CA, UNITED STATES  
Lacey, David Lee, Newbury Park, CA, UNITED STATES  
Boone, Thomas Charles, Newbury Park, CA, UNITED STATES

PATENT ASSIGNEE(S): Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168363	A1	20021114
APPLICATION INFO.:	US 2001-840277	A1	20010423 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201394P	20000503 (60)
	US 2000-198919P	20000421 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	1929	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns fusion of half-life extending vehicles, preferably Fc domains, with peptide sequences that act as antagonists of integrins, selectins, cell adhesion molecules, or their respective receptors. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The peptide may be an existing peptide or a peptide selected by phage display, E. coli display, ribosome display, RNA-peptide screening, chemical-peptide screening, or other methods.

DETD [0135] **endocrine osteoporosis** (hyperthyroidism, **hyperparathyroidism**, Cushing's syndrome, and acromegaly);

L1 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:171897 USPATFULL

TITLE: Calcitonin-related molecules

INVENTOR(S): Liu, Chuan-Fa, Longmont, CO, UNITED STATES  
 Marshall, William S., Boulder, CO, UNITED STATES  
 Reynolds, Angela, Evergreen, CO, UNITED STATES  
 PATENT ASSIGNEE(S): Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002090646	A1	20020711
APPLICATION INFO.:	US 2001-847712	A1	20010502 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201511P	20000503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	U.S. Patent Operations/ TJG, Dept. 4300, M/S 27-4-A, AMGEN INC., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	1677	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns therapeutic agents that modulate the activity of CT receptor. In accordance with the present invention, modulators of CT receptor comprise:

a. a CT receptor modulating domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and

b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred;

wherein the vehicle is covalently attached to the CT receptor modulating domain. The vehicle and the CT receptor modulating domain may be linked through the N- or C-terminus of the CT receptor modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred CT receptor modulating domains comprise the amino acid sequences described in Table 1. Other CT receptor modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein.

Further in accordance with the present invention is a process for making CT receptor modulators, which comprises:

a. selecting at least one peptide that binds to the CT receptor; and

b. covalently linking said peptide to a vehicle.

The preferred vehicle is an Fc domain. Step (a) is preferably carried out by selection from the peptide sequences in Table 1 hereinafter or from phage display, RNA-peptide screening, or the other techniques mentioned herein.

DETD [0178] **endocrine osteoporosis** (hyperthyroidism, **hyperparathyroidism**, Cushing's syndrome, and acromegaly);

=>





L2 ANSWER 3 OF 233 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2000:867130 CAPLUS  
DOCUMENT NUMBER: 134:278558  
TITLE: The role of parathyroid hormone and  
**hyperparathyroidism in osteoporosis**  
AUTHOR(S): D'Amour, Pierre  
CORPORATE SOURCE: Department of Medicine, Universite de Montreal, Centre  
de Recherche Clinique, Hopital St Luc, Montreal, QC,  
H2X 1P1, Can.  
SOURCE: Osteoporosis Primer (2000), 211-224. Editor(s):  
Henderson, Janet E.; Goltzman, David. Cambridge  
University Press: Cambridge, UK.  
CODEN: 69ASDQ  
DOCUMENT TYPE: Conference; General Review  
LANGUAGE: English  
AB A review, with 68 refs., discussing how PTH and factors affecting PTH  
concn. and/or biol. effects are involved in the development of primary and  
secondary osteoporosis.  
REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

3 / 53 / 113 / 103  
34  
66